Alnylam Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Alnylam Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Alnylam Pharmaceuticals Inc achieved a return on average assets (ROA) of 45.99 % in its third quarter of 2026, this is above ALNY's average return on assets of -22.87%.
Alnylam Pharmaceuticals Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $5 billion

ROA has improved compared to 16.54% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 20 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 470, from total ROA ranking in the second quarter of 2026 at 859.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	64.78 %	21.74 %	22.26 %	23.18 %	20.96 %
Y / Y Net Income Change	640.51 %	-	-	-	-
Net Income (TTM) in million	2,724	850	613	389	118
Return On Assets (TTM)	45.99 %	16.54 %	12.53 %	8.35 %	2.68 %
ALNY's Total Ranking	# 470	# 859	# 1681	# 3142	# 3115
Total Assets (TTM) in million	7,995	5,559	5,152	4,989	4,852
Seq. Total Assets Change	43.82 %	7.9 %	3.27 %	2.82 %	6.26 %
Seq. Net Income Change	1217.58 %	-20.15 %	10.5 %	-36.31 %	-

ALNY's 5 Years Annual ROA >> Back to ALNY Management Effectiveness >> Compare ALNY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 11
Sector	# 21
Overall	# 73

Return On Assets Statistics
High	Average	Low
46.08 %	-22.87 %	-54.94 %
(Sep 30 2026)		(Mar 31 2014)

News about Alnylam Pharmaceuticals Inc Return on Assets ROA

Alnylam Pharmaceuticals Unveils Promising Data on Vutrisiran for ATTR Amyloidosis with Cardiomyopathy at HFSA Annual ...

In a significant advancement in the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) recently showcased compelling findings from the HELIOS-B Phase 3 clinical study of vutrisiran. This investigational RNA interference (RNAi) therapeutic was highlighted during the Late Breaking Clinical Research Session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which took place virtually. The HELIOS-B study represents a landmark in the ongoing effort to address the complexities of ATTR-CM, a severe condition often marked by progressive heart failure linked to the accumulation of amyloid proteins. Results discussed during the session demonstrated that vutrisiran met its primary endpoint, reflecting its considerable potential to mitigate cardiac challenges associated with this condition. The presentation ignited interest among cardiologists and researchers, underscoring the critical need for effective treatments that not only address disease symptoms but also target the underlying pathology of amyloidosis.Looking ahead, Alnylam is set to continue its momentum, with plans to present detailed results of the HELIOS-B study at the European Society of Cardiology (ESC) Congress 2024, scheduled for August 30 to September 2 in London, UK. This platform will provide an opportunity to delve deeper into the data and engage with a global audience, further enhancing the visibility and relevance of vutrisiran within the cardiovascular therapeutic landscape. The prospect of revealing additional insights at such a prestigious gathering amplifies the anticipation surrounding the treatment s future.

Financial Statements
Alnylam Pharmaceuticals Inc 's Assets	$ 7,995 million	ALNY's Balance sheet
Alnylam Pharmaceuticals Inc 's Income	$ 2,167 million	Quarterly ALNY's Income Statement
ALNY's Income by Division		See ALNY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	23.18 %	11.53 %	8.97 %	-2.41 %	7.79 %
Total Assets in million	4,989	4,050	3,631	3,332	3,414
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	314	-278	-440	-1,131	-853
Annual Return On Assets	6.29 %	-6.87 %	-12.12 %	-33.95 %	-24.98 %

ALNY's 5 Years Annual ROA >> Back to ALNY Management Effectiveness >> Compare ALNY ROA to its Competitors

Comment on ALNY's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.29 % compared to prior year, due to annual net income growth of % to $313.75 million, while value of Alnylam Pharmaceuticals Inc 's overall assets grew just by 23.18 % to $4,988.50 million, compared to $4,988.50 a year before.

More Return On Assets Ratios
ALNY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ALNY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ALNY's Competitors
Subscribers only: Roa for Alnylam Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ALNY's Customers

You may also want to know
ALNY's Roi	ALNY's Inventory Turnover Ratio	ALNY's Growth Rates	ALNY's Dividend Comparisons
	ALNY's Profitability Ratios	ALNY's Asset Turnover Ratio	ALNY's Dividend Growth
ALNY's Roe	ALNY's Valuation Ratios	ALNY's Financial Strength Ratios	ALNY's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-10-30T17:00:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.